Compile Data Set for Download or QSAR
Report error Found 410 Enz. Inhib. hit(s) with all data for entry = 13210
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767149(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  0.813nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767135(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  0.843nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767081(N-[3-(4,6-dimethylpyrimidin-5-yl)-4-(2-pyrrolidin-...)
Affinity DataKi:  0.845nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767275((R)-N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(piperidin...)
Affinity DataKi:  1.03nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767129(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  1.11nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767092(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  1.30nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767126(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  1.48nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767235(N-[3-(4,6-dimethylpyrimidin-5-yl)-4-[2-(3-fluoroaz...)
Affinity DataKi:  1.48nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767145(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  1.58nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767129(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataIC50: 1.68nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767151(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  1.70nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767271((R)-N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(piperidin...)
Affinity DataKi:  1.70nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767133(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  1.70nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767174(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  1.70nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767143(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  1.71nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767094(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  1.72nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767210(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-((2- metho...)
Affinity DataKi:  1.73nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767165(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  1.77nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767208(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-((2- metho...)
Affinity DataKi:  1.99nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767116(N-[3-(4,6-dimethylpyrimidin-5-yl)-4-(2-pyrrolidin-...)
Affinity DataKi:  2.01nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767086(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  2.05nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767055((1S,2R)-N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(py...)
Affinity DataKi:  2.08nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767149(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataIC50: 2.38nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767127(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  2.43nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767080(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  2.48nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767136(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  2.61nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767218(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-((2- metho...)
Affinity DataKi:  2.64nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767138(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  2.65nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767120(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  2.71nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767207(N-(4-(azetidin-3-yloxy)-3-(4,6-dimethylpyrimidin-5...)
Affinity DataKi:  2.87nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767147(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  3.01nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767135(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataIC50: 3.07nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767130((1s,3s)-N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(py...)
Affinity DataKi:  3.18nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767061(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  3.25nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767125(N-[3-(4,6-dimethylpyrimidin-5-yl)-4-(2-pyrrolidin-...)
Affinity DataKi:  3.26nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767141(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  3.28nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767145(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataIC50: 3.31nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767168(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  3.39nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767128(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  3.40nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767212(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-((2- metho...)
Affinity DataKi:  3.44nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767163(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  3.62nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767232(N-[4-[2-[(1R, 5S)-3-azabicyclo[3.1.0]hexan-3-yl]et...)
Affinity DataKi:  3.63nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767013(N-[3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  3.72nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767170(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  3.77nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767051(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  3.81nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767105(N-[3-(4,6-dimethylpyrimidin-5-yl)-4-(2-pyrrolidin-...)
Affinity DataKi:  3.86nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767131(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  3.92nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767171((R)-N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(3-meth...)
Affinity DataKi:  4.06nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767161(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(4,6-dimethylpyri...)
Affinity DataKi:  4.09nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM767115(N-(3-(4,6-dimethylpyrimidin-5-yl)-4-(2-(pyrrolidin...)
Affinity DataKi:  4.11nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Displayed 1 to 50 (of 410 total ) | Next | Last >>
Jump to: